PMID- 23506230
OWN - NLM
STAT- MEDLINE
DCOM- 20140331
LR  - 20220311
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 12
IP  - 4
DP  - 2013 Jul
TI  - Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative 
      meta-analysis of 89 randomized controlled trials.
PG  - 465-77
LID - 10.1517/14740338.2013.780595 [doi]
AB  - OBJECTIVE: Further understand the safety profile of celecoxib and provide safety 
      information for important adverse events (AEs). METHODS: Analysis of randomized 
      controlled trials from the Pfizer clinical trial repository (final study reports 
      completed by 31 July 2011) in which celecoxib was compared with placebo or 
      non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) for treatment of 
      pain or inflammation in adults. Safety end points comprised 18 terms that had 
      been identified as important AEs among all NSAIDs. RESULTS: There was a greater 
      risk of edema (risk difference (95% confidence interval) 0.77% (0.45, 1.09)); 
      hypertension (0.28% (-0.01, 0.57)); angioedema (0.16% (-0.06, 0.39) and allergic 
      reactions (0.15% (-0.10, 0.40)) with celecoxib than with placebo, while a greater 
      risk of gastrointestinal (GI) hemorrhage (-0.15% (-0.47, 0.16)) was seen with 
      placebo. There was a greater risk of GI hemorrhage (-0.53% (-0.72, -0.33)), GI 
      ulceration (-0.46% (-0.60, -0.33)), edema (-0.62% (-0.89, -0.35)) and 
      hypertension (-0.57% (-0.82, -0.33)) with nsNSAIDs than with celecoxib. 
      CONCLUSIONS: The magnitude of risks associated with NSAIDs is small and similar 
      in celecoxib-, nsNSAID- and placebo-treated patients. This analysis provides 
      safety information that will allow physicians to make informed treatment 
      decisions for patients who are appropriate candidates for celecoxib use.
FAU - Essex, Margaret Noyes
AU  - Essex MN
AD  - US Medical Affairs, Pfizer Inc., 235 E. 42nd Street, New York, NY 10017, USA. 
      Margaret.essex@pfizer.com
FAU - Zhang, Richard Y
AU  - Zhang RY
FAU - Berger, Manuela F
AU  - Berger MF
FAU - Upadhyay, Sameer
AU  - Upadhyay S
FAU - Park, Peter W
AU  - Park PW
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20130319
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
EIN - Expert Opin Drug Saf. 2013 Nov;12(6):913
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use
MH  - Celecoxib
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase 2 Inhibitors/*adverse effects/therapeutic use
MH  - Female
MH  - Humans
MH  - Inflammation/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pain/drug therapy
MH  - Pyrazoles/*adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sulfonamides/*adverse effects/therapeutic use
EDAT- 2013/03/20 06:00
MHDA- 2014/04/01 06:00
CRDT- 2013/03/20 06:00
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2014/04/01 06:00 [medline]
AID - 10.1517/14740338.2013.780595 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2013 Jul;12(4):465-77. doi: 10.1517/14740338.2013.780595. 
      Epub 2013 Mar 19.